Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals
(NQ:
ALNY
)
222.90
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alnylam Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Nvidia, Affirm Holdings, Carnival Corp, Alnylam Pharmaceuticals, Tesla: Why These 5 Stocks Are On Investors' Radars Today
June 24, 2024
On Monday, major U.S. indices showed mixed performance. The Dow Jones Industrial Average closed up by nearly 0.7% at 39,411.21,
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Semiconductor, Nvidia Woes Deepen; Nasdaq 100 Slips, Dow Rallies; Bitcoin Sinks To $60,400: What's Driving Markets Monday?
June 24, 2024
Wall Street faces a continuation of last week’s trend during Monday’s morning trading, with semiconductor stocks selling off heavily and dragging down the tech sector, while the broader market remains...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears
June 24, 2024
A 2024 coffee recall is in effect for products made by Snapchill LLC due to concerns of botulism from the FDA for hundreds of canned coffees.
Via
InvestorPlace
Exposures
Product Safety
Behind the Scenes of Alnylam Pharmaceuticals's Latest Options Trends
June 12, 2024
Via
Benzinga
(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest
May 17, 2024
Via
Benzinga
How Is The Market Feeling About Alnylam Pharmaceuticals?
April 19, 2024
Via
Benzinga
Alnylam (ALNY) Stock Soars 30% on Heart Disease Drug Success
June 24, 2024
The challenge for Alnylam now will be to find and diagnose patients with the condition known as ATTR-CM, which is considered rare.
Via
InvestorPlace
Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge
June 24, 2024
Alnylam Pharmaceuticals reports positive results from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardiomyopathy. The trial showed significant reductions in mortality and...
Via
Benzinga
Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug
June 24, 2024
The companies are working on treatments for ATTR amyloidosis with cardiomyopathy.
Via
Investor's Business Daily
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
June 24, 2024
Via
Benzinga
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
June 24, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Masters In Trading - Saturday, June 22
June 22, 2024
In this video, I discuss a stock that is expected to see major upside, and I take a closer look at my portfolio.
Via
Talk Markets
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today
June 14, 2024
Via
Benzinga
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
June 13, 2024
Via
Benzinga
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
June 05, 2024
Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
May 09, 2024
Via
Benzinga
Alnylam Issues 2023 Corporate Responsibility Report
May 07, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
ALNY Stock Earnings: Alnylam Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
May 02, 2024
ALNY stock results show that Alnylam Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
May 02, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
April 18, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
April 09, 2024
Via
Benzinga
Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data
April 08, 2024
The latest findings from Alnylam Pharmaceuticals' KARDIA-2 Phase 2 study are on zilebesiran's efficacy and safety in treating hypertension. Results show significant reductions in systolic blood...
Via
Benzinga
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
April 07, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
April 02, 2024
Via
Benzinga
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
March 28, 2024
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
Via
Investor's Business Daily
Exposures
Product Safety
3 Biotech Stocks to Buy on the Dip: March 2024
March 27, 2024
Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three.
Via
InvestorPlace
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
March 20, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years
March 18, 2024
Via
Benzinga
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
March 13, 2024
One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses.
Via
InvestorPlace
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
March 13, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.